Lomitapide as a Novel Therapeutic Agent in Breast Cancer: Mechanism and Potential Implications

Area of Science:

• Oncology
• Pharmacology
• Drug Discovery

Background:

• Breast cancer heterogeneity and drug resistance necessitate novel therapeutic strategies.
• Drug repurposing offers a promising avenue for identifying new anti-cancer agents.

Purpose of the Study:

• To identify potential anti-breast cancer compounds through drug repurposing.
• To evaluate the efficacy and mechanisms of action of candidate drugs in breast cancer cells.

Main Methods:

• Screening of 192 FDA-approved drugs to identify anti-cancer candidates.
• In vitro evaluation of lomitapide's effects on MDA-MB-231 and MCF-7 breast cancer cell lines.
• Virtual screening and experimental validation to identify molecular targets.

Main Results:

• Lomitapide significantly inhibited breast cancer cell proliferation, invasion, and migration.
• Lomitapide directly interacted with estrogen receptor-alpha (ER-α) and peroxisome proliferator-activated receptor gamma (PPARγ).
• Lomitapide enhanced the sensitivity of MCF-7 cells to tamoxifen, an endocrine therapy.

Conclusions:

• Lomitapide demonstrates multi-mechanistic suppression of breast cancer progression.
• Lomitapide is a potential repurposed agent for breast cancer treatment.
• ER-α and PPARγ are identified as potential therapeutic targets for lomitapide-mediated anti-cancer effects.